Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint
has demonstrated unprecedented clinical efficacy in the treatment of advanced cancers …

B-cell lymphoma is a group of hematological malignancies with high clinical and biological
heterogeneity. The pathogenesis of B-cell lymphoma involves a complex interaction …

Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …

Abstract PD-1/L1 and CTLA-4 blockade immunotherapies have been approved for 13 types
of cancers and are being studied in diffuse large B-cell lymphoma (DLBCL), the most …

The incidence of lymphoma has gradually increased over previous decades, and it ranks
among the ten most prevalent cancers worldwide. With the development of targeted …

Cancer cells subvert host immune surveillance by altering immune checkpoint (IC) proteins.
Some Epstein− Barr virus (EBV)-associated tumors have higher Programmed Cell Death …

Nasal natural killer/T-cell lymphoma (NNKTL) is an aggressive neoplasm with poor
therapeutic responses and prognosis. The programmed death-1/programmed death-ligand …

Abstract Purpose of Review Programmed cell death protein-1 (PD-1) is currently the most
extensively studied inhibitory checkpoint molecule. Many malignant neoplasms express the …

Immunodeficiency-associated lymphoproliferative disorders (IA-LPDs) are pathologically
and clinically heterogeneous. In many instances, similar features are shared by a spectrum …

Tumor programmed death‐ligand 1 (PD‐L1) expression in diffuse large B‐cell lymphoma
(DLBCL) is associated with inferior outcomes. The first‐line immunologically‐replete setting …